Wildcat Capital Management, LLC - UROGEN PHARMA LTD ownership

UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 32 filers reported holding UROGEN PHARMA LTD in Q3 2017. The put-call ratio across all filers is - and the average weighting 1.6%.

Quarter-by-quarter ownership
Wildcat Capital Management, LLC ownership history of UROGEN PHARMA LTD
ValueSharesWeighting
Q3 2023$6,943,440
+35.4%
495,6060.0%2.79%
+42.9%
Q2 2023$5,129,522
+12.0%
495,6060.0%1.95%
+14.7%
Q1 2023$4,579,399
-3.2%
495,606
-7.0%
1.70%
-5.7%
Q4 2022$4,728,943
+6.6%
533,1390.0%1.80%
+5.9%
Q3 2022$4,436,000
+1.6%
533,1390.0%1.70%
+17.9%
Q2 2022$4,366,000
-6.0%
533,1390.0%1.45%
+21.7%
Q1 2022$4,644,000
-8.4%
533,1390.0%1.19%
+43.8%
Q4 2021$5,070,000
-43.5%
533,1390.0%0.83%
-28.9%
Q3 2021$8,967,000
+10.1%
533,1390.0%1.16%
+25.6%
Q2 2021$8,141,000
-21.6%
533,1390.0%0.92%
-27.1%
Q1 2021$10,386,000
-54.0%
533,139
-57.4%
1.27%
-55.3%
Q4 2020$22,566,000
-6.6%
1,252,2850.0%2.84%
-63.3%
Q3 2020$24,156,000
+2.7%
1,252,285
+39.1%
7.72%
-4.9%
Q2 2020$23,512,000
+46.4%
900,1480.0%8.12%
+11.1%
Q1 2020$16,058,000
-58.4%
900,148
-22.1%
7.31%
-34.3%
Q4 2019$38,571,000
+53.3%
1,155,862
+9.5%
11.13%
+4.1%
Q3 2019$25,166,000
-17.0%
1,056,062
+25.2%
10.69%
-18.5%
Q2 2019$30,311,000
+5.3%
843,365
+8.3%
13.12%
-22.2%
Q1 2019$28,776,000
+9.1%
779,003
+27.2%
16.86%
-2.7%
Q4 2018$26,374,000
+48.7%
612,494
+63.1%
17.34%
+26.7%
Q3 2018$17,734,000
+41.7%
375,479
+49.3%
13.68%
+42.9%
Q2 2018$12,513,000
+38.6%
251,459
+38.4%
9.57%
+28.5%
Q1 2018$9,029,000
+90.6%
181,702
+42.7%
7.45%
+47.7%
Q4 2017$4,738,000
+11.4%
127,313
-5.7%
5.04%
+560.7%
Q3 2017$4,255,000
+74.5%
135,0000.0%0.76%
+17.7%
Q2 2017$2,439,000135,0000.65%
Other shareholders
UROGEN PHARMA LTD shareholders Q3 2017
NameSharesValueWeighting ↓
ProQuest Associates IV LLC 789,297$39,275,00060.44%
Wildcat Capital Management, LLC 251,459$12,513,0009.57%
Consonance Capital Management LP 1,487,491$74,018,0004.77%
MENORA MIVTACHIM HOLDINGS LTD. 2,499,870$124,394,0003.53%
MEITAV INVESTMENT HOUSE LTD 509,355$29,967,0001.34%
DSAM Partners (London) Ltd 127,588$6,349,0001.28%
SHIKIAR ASSET MANAGEMENT INC 48,125$2,395,0001.00%
BANK HAPOALIM BM 67,125$3,340,0000.91%
HIGHLINE CAPITAL MANAGEMENT, L.P. 331,900$16,515,0000.55%
Clal Insurance Enterprises Holdings Ltd 310,000$15,426,0000.40%
View complete list of UROGEN PHARMA LTD shareholders